Drug intelligence / Profile preview

PLX-IBD

Development stage: Preclinical
Lead developer: Pluri
Modality: Cell Therapies

Overview

PLX-IBD is an allogeneic placental-derived cell therapy product developed by Pluristem Therapeutics Inc. (via its wholly owned subsidiary, Pluristem Ltd.) for the treatment of Inflammatory Bowel Disease. The development of PLX-IBD has been supported by grants from the Israeli Ministry of Industry, Trade and Labor, specifically for research and development and clinical trials of PLX cell therapies.

Beyond the preview

Go deeper on PLX-IBD.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on PLX-IBD.